Celularity (Celularity) EBIT : $-179.04 Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Celularity EBIT?

Celularity's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-92.91 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-179.04 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Celularity's annualized ROC % for the quarter that ended in Sep. 2023 was -31.09%. Celularity's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -443.96%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Celularity's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -131.27%.

Celularity EBIT Historical Data

The historical data trend for Celularity's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celularity EBIT Chart

Celularity Annual Data

Trend

Dec20

Dec21

Dec22

EBIT

-210.58

-96.93

14.21

Celularity Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT	Get a 7-Day Free Trial									4.78	24.45	-63.74	-46.85	-92.91

Competitive Comparison of Celularity's EBIT

For the Biotechnology subindustry, Celularity's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celularity's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celularity's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Celularity's EV-to-EBIT falls into.

Celularity EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-179.04 Mil.

Celularity (NAS:CELU) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Celularity's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-66.168 * ( 1 - 0% )	/	( (247.509	+	178.156)	/ 2 )
=	-66.168	/	212.8325
=	-31.09 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	246.419	-	45.849	-	( 3.084	-	max(0, 64.976	-	18.037	+	3.084	))
=	247.509

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	157.192	-	47.17	-	( 0.273	-	max(0, 84.632	-	16.498	+	0.273	))
=	178.156

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Celularity's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-371.62	/	( ( (85.724 + max(-35.279, 0))	+	(81.686 + max(-35.475, 0)) )	/	2 )
=	-371.62	/	( ( 85.724	+	81.686 )	/	2 )
=	-371.62	/	83.705
=	-443.96 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.812	+	5.738	+	4.331)	-	(45.849	+	2.311	+	0)
=	-35.279

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.114	+	4.934	+	5.105)	-	(47.17	+	2.458	+	0)
=	-35.475

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Celularity's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	-179.043	/	136.392
	=	-131.27 %

Celularity EBIT Related Terms

Thank you for viewing the detailed overview of Celularity's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Celularity (Celularity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celularity Inc (NAS:CELU) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

170 Park Avenue, Florham Park, NJ, USA, 07932

Website

https://www.celularity.com

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Executives

Kok Thay Lim	director	22ND FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Robert J Hariri	director, officer: Chief Executive Officer	341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Ling Geoffrey M.d.	director	C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710, SOUTH SAN FRANCISCO CA 94080
Berhad Genting	10 percent owner	24TH FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Adrian Kilcoyne	officer: See Remarks	533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
John Sculley	director	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kyle Fletcher	officer: General Counsel	CELULARITY INC., 170 PARK AVE., FLORHAM PARK NJ 07932
Peter Diamandis	director	4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292
Dean C Kehler	director	C/O TRIMARAN CAPITAL PARTNERS, 622 THIRD AVENUE, 35TH FLOOR, NEW YORK NY 10017
Robin L Smith	director	C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Marc Mazur	director	31 WEST 52ND ST. 17TH FLOOR, NEW YORK NY 10019
Diane L. Parks	director	29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Bradley Glover	director, officer: Chief Technology Officer	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Stephen Brigido	officer: Pres, Functional Regeneration	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Anne Jones	director, officer: Chief Business Officer	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932